# Flashpoint Therapeutics

> Flashpoint Therapeutics is a clinical-stage biotech spun out of Chad Mirkin's nanotechnology lab at Northwestern University, developing 'structural nanomedicines' - drugs whose potency comes not from new molecules but from how existing therapeutic components are arranged at the nanoscale. By co-delivering RNA, DNA, peptide and CRISPR payloads to individual cells with precise stoichiometry and synchronized activation, the company reports it can turn conventionally ineffective drug components into curative therapies, with early data showing dramatically stronger immune activation and tumor killing. Founded by Adam Margolin and backed by a $10M seed round led by Riyadh-based Beta Lab plus a $50M KAIMRC partnership, Flashpoint is advancing its lead immuno-oncology candidate FLASH-001 through the clinic.

- **Founded:** 2023
- **Headquarters:** Evanston, Illinois, United States
- **Founders:** Adam Margolin (Founder & founding CEO (departed 2025)), Chad Mirkin (Scientific Co-Founder & Board Member), Michelle Teplensky (Scientific Founder)
- **Team size:** ~16 employees
- **Products:** Structural Nanomedicine Platform, FLASH-001, Immuno-oncology pipeline
- **Notable:** Assembled 150+ issued patents and patent applications spanning nucleic acid, protein and CRISPR gene editing therapeutics, Reported 35x increased co-delivery to immune cells, 80x stronger immune activation, and 650% greater tumor killing vs conventional formulations, Closed $10M seed financing led by Beta Lab (October 2023)

## Products & services

- **Structural Nanomedicine Platform** — A nanotechnology-based discovery platform that co-delivers diverse RNA, DNA, peptide and CRISPR cargo to target cells with precise stoichiometry, optimized structure-function relationship, and synchronized activation kinetics.
- **FLASH-001** — Lead clinical program - a structural nanomedicine using toll-like receptor 9 (TLR9) agonists for immuno-oncology; early Phase 1b/2 data reported curative effects in a subset of Merkel Cell Carcinoma patients.
- **Immuno-oncology pipeline** — Preclinical candidates validated across breast cancer, lymphoma, cervical cancer, melanoma, colon cancer, glioma and prostate cancer, plus programs in neurology and other indications.

## Achievements

- Assembled 150+ issued patents and patent applications spanning nucleic acid, protein and CRISPR gene editing therapeutics
- Reported 35x increased co-delivery to immune cells, 80x stronger immune activation, and 650% greater tumor killing vs conventional formulations
- Closed $10M seed financing led by Beta Lab (October 2023)
- Secured $50M KAIMRC partnership and established a Center of Excellence in Structural Nanomedicine (November 2024)
- Advanced lead candidate FLASH-001 into Phase 1b/2 with reported curative effects in a subset of Merkel Cell Carcinoma patients
- Recruited biopharma veteran Barry Labinger (ex-Checkmate Pharmaceuticals CEO) as Chief Executive Officer (July 2025)

## Latest updates

- **2025-07** — Appointed Barry Labinger (former Checkmate Pharmaceuticals CEO) as Chief Executive Officer; founding CEO Adam Margolin departed.
- **2024-11** — Announced $50M partnership with KAIMRC and expansion of clinical pipeline, including FLASH-001 in immuno-oncology.
- **2023-10** — Announced $10M seed financing led by Beta Lab to pioneer nanotechnology-enabled medicines.

## Links

- Website: https://www.flashpoint.bio
- LinkedIn: https://www.linkedin.com/company/flashpoint-therapeutics

---

Profile page: https://yespress.io/flashpoint-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-08-05